Nivolumab-Associated Colitis Mimicking Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 9, 2017, Pages A35-A36

  Kubo, Kimitoshi ^a   Kato, Mototsugu ^a   Mabe, Katsuhiro ^a  

^a National Hospital Organization Hakodate Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MESALAZINE; NIVOLUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; AGED; ARTICLE; CANCER RECURRENCE; CASE REPORT; CELL INFILTRATION; CLINICAL FEATURE; COLITIS; COLON BIOPSY; COLONOSCOPY; CRYPT CELL; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENDOSCOPY; EOSINOPHIL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; INTESTINE CRYPT; LAMINA PROPRIA; LYMPHOCYTE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL CHEMOTAXIS; NIVOLUMAB ASSOCIATED COLITIS; NON SMALL CELL LUNG CANCER; PLASMA CELL; SUBMUCOUS PLEXUS; ULCERATIVE COLITIS; VERY ELDERLY; CHEMICALLY INDUCED; CYTOCHEMISTRY; MICROSCOPY; PATHOLOGY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COLITIS, ULCERATIVE; COLONOSCOPY; HISTOCYTOCHEMISTRY; HUMANS; MALE; MICROSCOPY; NIVOLUMAB;

EID: 85020808272     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.03.026     Document Type: Article

References (4)

1. Gupta, A., De Felice, K.M., Loftus, E.V. Jr., et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42 (2015), 406–417.
2. Berman, D., Parker, S.M., Siegel, J., et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun, 10, 2010, 11.
3. Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 (2016), 51–60.
4. Minor, D.R., Chin, K., Kashani-Sabet, M., Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 24 (2009), 321–325.